เปรียบเทียบวิธี

	การทดลองแฟกทอเรียลแบบเศษส่วนแบบปกปิดฝ่ายเดียว	การทดลองสุ่มและมีกลุ่มควบคุมแบบปกปิดฝ่ายเดียว
สาขาวิชา	การออกแบบการทดลอง	การออกแบบการทดลอง
ตระกูล	Process / pipeline	Process / pipeline
ปีกำเนิด	1940s–1950s (fractional factorial foundations); blinding conventions formalised through 1960s–1980s	1948 (formalized); single-blind variant established in mid-20th century clinical trial methodology
ผู้ริเริ่ม	Fractional factorial theory: R. L. Plackett & J. P. Burman (1946); single-blinding practice codified in clinical trial methodology (20th century)	Bradford Hill and colleagues (MRC streptomycin trial, 1948); blinding conventions codified in CONSORT guidelines
ประเภท	Controlled experimental design	Experimental design — blinded randomized trial
แหล่งต้นตำรับ	Box, G. E. P., Hunter, J. S., & Hunter, W. G. (2005). Statistics for Experimenters: Design, Innovation, and Discovery (2nd ed.). Wiley-Interscience. ISBN: 978-0471718130	Schulz, K. F., Altman, D. G., Moher, D., & CONSORT Group. (2010). CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials. BMJ, 340, c332.
ชื่อเรียกอื่น	single-masked fractional factorial, single-blind FFD, partially blinded fractional factorial, single-blind 2^(k-p) design	single-masked RCT, single-blind RCT, single-blind trial, SB-RCT
ที่เกี่ยวข้อง	5	5
สรุป	A single-blind fractional factorial experiment studies multiple factors simultaneously by testing only a strategically chosen subset — a fraction — of all possible factor-level combinations, while keeping participants unaware of which treatment condition they receive. This design yields substantial information about main effects and selected interactions at a fraction of the cost of a full factorial experiment, with single-blinding reducing participant-side response bias.	A single-blind randomized controlled trial (SB-RCT) is a rigorous experimental design in which participants are randomly assigned to treatment or control conditions while remaining unaware of which condition they have received. Investigators, outcome assessors, and data analysts are not blinded. By masking participants, the design eliminates placebo and nocebo response biases on the participant side, while preserving investigator flexibility to administer and monitor the intervention.